DB05061ExperimentalSmall molecule
GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of... GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides) and on other...
- Mechanism
- Curator reviewed
GFT14 is a synthetic modified triglyceride that agonizes PPAP alpha. It raises HDL-C and lowers triglycerides.
- Primary indication
- Investigated for use/treatment in cardiovascular disorders and hyperlipidemia.Curator reviewed
- Code names
- GFT14
Which companies are running trials of GFT14, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account